Sarcopenia and polypharmacy among older adults: A scoping review of the literature

• Published in: Archives of gerontology and geriatrics 2022-01, Vol.98, p.104520-104520, Article 104520
• Main Authors: Pana, Anastasia, Sourtzi, Panayota, Kalokairinou, Athina, Velonaki, Venetia Sofia
• Format: Article
• Language: English
• Subjects: Aged; Cross-Sectional Studies; Humans; Independent Living; Multiple medication; Number of medications; Polypharmacy; Quality of Life; Sarcopenia; Sarcopenia - epidemiology
• ISSN: 0167-4943; 1872-6976
• DOI: 10.1016/j.archger.2021.104520

•Sarcopenia is associated with polypharmacy in community-dwelling older adults.•No association found between sarcopenia and polypharmacy in nursing home residents.•Among inpatients no relationship between sarcopenia and polypharmacy observed.•Further research is needed to identify polypharmacy as risk factor for sarcopenia. Sarcopenia and polypharmacy are both prevalent conditions in the geriatric population, leading to poor quality of life and adverse outcomes. To explore the evidence on the relationship between sarcopenia and polypharmacy and to summarize the findings and the gaps from the existing literature. A systematic scoping review was conducted between March and May 2021, with no restriction on publication date, using the Arksey and O'Malley framework and reported according to PRISMA-ScR. Four bibliographic databases, PubMed, Web of Science, Scopus, Proquest One Academic, and four sources of gray literature were searched for studies written in English or Greek. Data were extracted quantitatively and using thematic analysis. Of the 397 initially retrieved records, 22 studies were finally included in this review, 20 published articles and 2 posters-presentations. Most of the studies used cross-sectional data. The relationship between sarcopenia and polypharmacy should be interpreted on the basis of the definition of polypharmacy, the diagnostic criteria of sarcopenia used, and the population setting. Sarcopenia or risk for sarcopenia are associated with polypharmacy or the number of medications in community-dwelling older adults, regardless of diagnostic criteria used for sarcopenia. There is an association between sarcopenia or risk for sarcopenia and polypharmacy or the number of medications in community-dwelling older adults but not among residents of nursing homes or inpatients. Specific widely accepted definitions of polypharmacy and sarcopenia, a consensus on the method of sarcopenia assessment, and prospective studies are needed to identify polypharmacy as a potential risk factor for sarcopenia. [Display omitted]